TIROSINT — Class II drug recall D-0341-2023
Terminated recall by IBSA PHARMA INC, reported 2023-03-01, distributed nationwide. Subpotent Drug
| Recall number | D-0341-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | IBSA PHARMA INC, Parsippany, NJ, United States |
| Recall initiated | 2023-01-30 |
| Classified | 2023-04-04 |
| Reported by FDA | 2023-03-01 |
| Terminated | 2023-10-31 |
| Distributed | Nationwide (US) |
| Reason classes | potency |
| NDC | 71858-0105, 71858-0105-01, 71858-0105-02, 71858-0105-04, 71858-0105-05, 71858-0105-06, 71858-0110, 71858-0110-01, 71858-0110-02, 71858-0110-04, 71858-0110-05, 71858-0110-06, 71858-0112, 71858-0112-01, 71858-0112-02, 71858-0112-04, 71858-0112-05, 71858-0112-06, 71858-0113, 71858-0113-01, 71858-0113-02, 71858-0113-04, 71858-0113-05, 71858-0113-06, 71858-0115 and 65 more |
| Lot numbers | 220411, 220854 |
| Expiration dates | 2023-10, 2024-02 |
Product
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL; 6 pouches x 5 ampules, Rx Only; Manufactured for IBSA Pharma Inc. by: IBSA Institut Biochimique SA, 6912 Pazzallo, Switzerland; Distributed by: IBSA Pharma Inc., Parsippany, NJ 07054; NDC 71858-0125-5
Reason for recall
Subpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0341-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.